VAGIFEM VAGINAL TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ESTRADIOL

Доступна с:

NOVO NORDISK CANADA INC

код АТС:

G03CA03

ИНН (Международная Имя):

ESTRADIOL

дозировка:

25MCG

Фармацевтическая форма:

VAGINAL TABLET

состав:

ESTRADIOL 25MCG

Администрация маршрут:

VAGINAL

Штук в упаковке:

15 TABLETS WITH APPLICATORS

Тип рецепта:

Prescription

Терапевтические области:

ESTROGENS

Обзор продуктов:

Active ingredient group (AIG) number: 0106457005; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2014-07-28

Характеристики продукта

_ _
_Vagifem_
_®_
_ (estradiol vaginal tablet) _
_Page 1 of 33_
PRODUCT MONOGRAPH
_PR_
VAGIFEM
®
17SS-ESTRADIOL
VAGINAL TABLET WITH APPLICATOR, 25 ΜG
ESTROGEN
Manufacturer’s Standard
Hormone Therapy
_NOVO NORDISK CANADA INC. _
300 – 2680 Skymark Ave.
Mississauga, Ontario
L4W 5L6
DATE OF REVISION:
12 July 2011
SUBMISSION CONTROL NO: 141555
_ _
_Vagifem_
_®_
_ (estradiol vaginal tablet) _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND
ADMINISTRATION..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL
INFORMATION..........................................................................22
CLINICAL
TRIALS...................................................................................